Mar 14, 2024 / 12:30PM GMT
Operator
Ladies and gentlemen, and welcome to the Autolus Therapeutics call to discuss the full year 2023 financial results and business time. (Operator Instructions) As a reminder, this conference call is being recorded. I would like to turn the conference over to your host, Olivia Manser. Please go ahead.
Olivia Manser - Autolus Therapeutics PLC - Investor Relations
Thank you, Suzanne. Good morning or good afternoon, everyone. Thanks for joining us on today's call. With me are Dr. Christian Itin, our Chief Executive Officer; and Rob Dolski, our Chief Financial Officer.
So on slide 2, before we begin, I'd just like to remind you that during today's call, we will make statements related to our business that are forward-looking and the federal securities laws and the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These may include, but are not limited to statements regarding the status of clinical trials and development and/or regulatory timelines for our product candidates and our expectations regarding our cash runway.
Q4 2023 Autolus Therapeutics PLC Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot